We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.38B
AUM Growth
-$480M
Cap. Flow
+$130M
Cap. Flow %
2.42%
Top 10 Hldgs %
41.73%
Holding
224
New
23
Increased
133
Reduced
36
Closed
13

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$23.8M
2
GKOS icon
Glaukos
GKOS
+$20.8M
3
ARVN icon
Arvinas
ARVN
+$19.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
5
PACB icon
Pacific Biosciences
PACB
+$13.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$72.6M
2
GILD icon
Gilead Sciences
GILD
+$33.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$23.2M
4
TDOC icon
Teladoc Health
TDOC
+$19.5M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.28%
2 Industrials 0.53%
3 Technology 0.51%
4 Financials 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOV
51
DELISTED
Myovant Sciences Ltd.
MYOV
$25M 0.47%
4,815,109
+905,000
+23% +$6.71M
ABMD
52
DELISTED
Abiomed Inc
ABMD
$23.7M 0.44%
133,031
-1,651
-1% -$357K
AMED
53
DELISTED
Amedisys
AMED
$23M 0.43%
175,658
+1,348
+0.8% +$175K
EVH icon
54
Evolent Health
EVH
$654M
$21.8M 0.4%
3,025,022
+676,022
+29% +$4.85M
QGEN icon
55
Qiagen
QGEN
$8.49B
$21.1M 0.39%
602,559
-99,558
-14% -$3.83M
INSM icon
56
Insmed
INSM
$23.5B
$21M 0.39%
1,191,480
+571,021
+92% +$11M
HRC
57
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$20.9M 0.39%
198,762
-34,436
-15% -$3.63M
TFX icon
58
Teleflex
TFX
$5.96B
$20.1M 0.37%
59,114
+22,348
+61% +$7.79M
LIVN icon
59
LivaNova
LIVN
$4.43B
$20M 0.37%
271,314
+5,648
+2% +$435K
ZBH icon
60
Zimmer Biomet
ZBH
$17.6B
$19.8M 0.37%
148,704
+44,469
+43% +$5.74M
SRRK icon
61
Scholar Rock
SRRK
$6.33B
$19.7M 0.37%
2,197,100
+245,261
+13% +$2.93M
ITCI
62
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$19.3M 0.36%
2,588,990
+343,490
+15% +$3.29M
ARVN icon
63
Arvinas
ARVN
$517M
$17.4M 0.32%
+806,403
New +$19.8M
TMO icon
64
Thermo Fisher Scientific
TMO
$198B
$16.7M 0.31%
57,236
+212
+0.4% +$60.7K
WMGI
65
DELISTED
Wright Medical Group Inc
WMGI
$16.6M 0.31%
804,291
+325,796
+68% +$7.75M
GTHX
66
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$16.4M 0.31%
721,925
+50,000
+7% +$1.58M
CDNA icon
67
CareDx
CDNA
$2.05B
$16.3M 0.3%
722,655
+230,647
+47% +$6.39M
GMED icon
68
Globus Medical
GMED
$10.5B
$15.2M 0.28%
297,666
+24,184
+9% +$1.15M
INSP icon
69
Inspire Medical Systems
INSP
$1.46B
$14.9M 0.28%
243,457
+49,117
+25% +$3.23M
PODD icon
70
Insulet
PODD
$11.4B
$14.7M 0.27%
89,245
+5,999
+7% +$843K
HMSY
71
DELISTED
HMS Holdings Corp.
HMSY
$14.2M 0.26%
411,972
+13,530
+3% +$489K
HCM icon
72
HUTCHMED
HCM
$1.86B
$13.8M 0.26%
788,198
+189,888
+32% +$3.95M
GNMK
73
DELISTED
GenMark Diagnostics, Inc
GNMK
$13.7M 0.26%
2,267,252
-85,815
-4% -$536K
IRTC icon
74
iRhythm Holdings
IRTC
$3.64B
$13.7M 0.25%
184,419
+5,571
+3% +$432K
IART icon
75
Integra LifeSciences
IART
$1.5B
$12.8M 0.24%
213,557
+21,824
+11% +$1.3M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2019 Portfolio in Review

As of Q3 2019, Bellevue Group held 224 positions worth $5.38B, down 8.2% from $5.86B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group's Q3 2019 filing shows 23 new, 133 increased, 36 reduced and 13 closed positions. Its largest new stake was Arvinas: 806,403 shares worth $17.4M. The largest sale was Celgene Corp, an estimated $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2019 buy was Arvinas: 806,403 shares worth $17.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2019, an estimated $23.8M increase.
  • Bellevue Group's biggest Q3 2019 reduction was Celgene Corp, cutting an estimated $72.6M.
  • Bellevue Group fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $15.8M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.38B portfolio in Q3 2019.
  • Bellevue Group opened 23 new positions and closed 13 in Q3 2019.
  • Bellevue Group's portfolio value fell 8.2% quarter-over-quarter to $5.38B.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.